Performance exploded—sending shockwaves across the entire market!

After adjusting for many consecutive days, China's A-share market finally staged a rebound today. The rebound was primarily driven by positive spillover effects from overseas markets. South Korea’s stock market surged so sharply early this morning that it triggered a circuit breaker. The two Korean market leaders—Samsung Electronics and SK Hynix—both saw their share prices surge nearly 10% at one point. The immediate catalyst was SK Hynix’s blockbuster Q3 earnings report. Revenue for the quarter reached 104.6 trillion KRW—the highest single-quarter revenue in the company’s history—up 32% quarter-on-quarter and a staggering 328% year-on-year. Operating profit hit 83.3 trillion KRW—up 38% quarter-on-quarter and an explosive 632% year-on-year. Its operating margin stood at a remarkable 80%, up four percentage points from 76% reported in its interim results. What does this mean? Among A-share liquor industry leaders, Kweichow Moutai’s operating margin is only 67.7%, while Wuliangye and Shanxi Xinghuacun Fenjiu report margins of just 42.21% and 41.91%, respectively. A memory chip manufacturer achieving higher profitability than *all* top-tier premium liquor companies in the A-share market is truly beyond imagination. Even more astonishing revelations followed. At the earnings call, SK Hynix’s CEO personally stated two key points: First: “Our DRAM and HBM production capacity is effectively sold out through 2029—i.e., over the next three years.” Second: “The tight supply-demand balance in the memory market is expected to persist until 2030.” As soon as these remarks were made, global semiconductor sector sentiment ignited—and at today’s market open, A-share subsectors including memory chips, optical modules, and computing hardware all surged sharply. ………… Additionally, the robotics sector performed strongly today, emerging as another major theme. Several developments contributed: First, last night Elon Musk responded to a netizen’s comment on “total memory demand for humanoid robots” with a telling remark—essentially stating that future humanoid robots’ memory requirements will far exceed those of any existing computing device. Second, Shanghai released its “Action Plan for Accelerating the Development of Next-Generation Intelligent Manufacturing,” which includes several concrete targets: By 2028: cultivate 500 advanced intelligent factories; expand AI application scenarios in manufacturing to over 2,000; develop 10 domain-specific large models; launch over 300 high-level intelligent agents; deploy 8,000 humanoid robots in factories; and raise industrial robot density to 600 units per 10,000 workers. Remember these ten words: “8,000 humanoid robots deployed in factories.” This is yet another recently issued domestic policy document intensively promoting the commercial rollout of humanoid robots. Recall last week Junlin’s analysis highlighting how high-level policy documents directly fueled the recent rally in humanoid robotics stocks? First came the central government’s implementation plan; then Shanghai’s local policy; and next, provinces across China are expected to roll out similar implementation documents one after another. Once policymakers have decided to push forward the real-world deployment of humanoid robots—and backed that decision with specific numerical targets—major moves are inevitable.

A safe haven amid the AI crash! Large-cap pharmaceutical stocks approach all-time highs.

On Thursday, the State Street SPDR Select Sector Fund—Health Care ETF hit a record high of $177.19, rising 5.6% over the past five trading days. Meanwhile, investors also flocked to consumer staples and U.S. Treasuries—triggered by the broad-based selloff in AI-related stocks, as concerns mounted over AI capital expenditure scale and Anthropic’s slowing revenue growth. Eli Lilly rose 3.4% on Thursday to close at its third-highest price ever; AbbVie closed at $283.40—the second-highest closing price in its history—just one day after setting a new all-time high of $283.48. Neither company announced major clinical data releases or M&A news; their gains stemmed purely from defensive fund rotation. Over the past five trading days, Gilead Sciences and Amgen rose 7.7% and 7.2%, respectively, while Merck gained 2.3%. UnitedHealth Group surged 9.1%, buoyed by strong Q3 earnings. Fund Rotation: AI Retreats, Pharma Steps Up According to MarketWatch, the heightened volatility in AI stocks is prompting investors to reassess the portfolio allocation value of large-cap pharmaceutical stocks. Their core appeal lies in stable, predictable earnings growth—driven by sustained R&D pipeline investment and extended patent life cycles for flagship drugs—offering a fundamentally different risk-return profile compared to tech stocks. As AI-related stocks face pressure amid debates over capital spending and downward revisions to growth expectations, investors simultaneously rotate into consumer staples and government bonds—highlighting the defensive attributes of the pharmaceutical sector. The State Street Health Care ETF hitting an all-time high is a direct reflection of this ongoing fund reallocation. Eli Lilly stands as one of the core beneficiaries of this pharmaceutical rally. Leveraging its dominant position in the GLP-1 weight-loss drug market, Lilly has become widely recognized as the industry’s most successful case study. Notably, this week’s price rise lacked any specific catalyst—instead exhibiting a consistent pattern: Lilly’s stock tends to rise whenever AI stocks encounter headwinds—or when major industry milestones occur. Even with its breakthrough success in the GLP-1 business, Lilly continues aggressive forward-looking investments.

Albemarle Jumps 5.5% Amid Sector-Wide Rally

4 days ago

Albemarle Corp stock surged 5.5% to $98.59 amid a specialty chemicals sector rally, outpacing peers despite recent analyst caution. Investors are watching for fundamental catalysts to sustain momentum.

AlphaStreet

2026-04-13

Copper Prices Surge Amid EV and Grid Demand; Mining ETFs Identified

2026-04-13

Albemarle (ALB) Surges 5.1% Amid Market Volatility

2026-04-16

Albemarle soars to nearly three-year high as lithium rebound sparks momentum

2026-04-18

Cwm LLC Increases Stake in Albemarle Corporation to $24.50 Million

2026-04-22

Rothschild Downgrades Albemarle Stock Rating on Lithium Pricing Lag